Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection

Summary

The purpose of this program is to provide pre-approval access to pimodivir for the treatment of a patient(s) with H7N9 influenza A infection. Pre-approval access pertains to provision for therapeutic use of an investigational product prior to its marketing authorization. Such access may be considered for eligible patients with serious/life-threatening diseases or conditions, where alternative treatments do not exist or have been exhausted.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications

No indication recorded.